AbbVie Inc. (0QCV)
LSE
Closed
Aug 24, 2026
Day's Range
262.0052 wk Range
186.49Overview - 0QCV - AbbVie Inc.
Key Statistics
Valuation
Enterprise Value
311.85B
P/E (Trailing)
‪54.73‬
PEG Ratio
‪0.19‬
Price / Sales (TTM)
‪8.54‬
Price / Book
‪36.48‬
EV / EBITDA
‪10.68‬
Profitability
Gross Margin
‪74.74%‬
Profit Margin
‪15.50%‬
Operating Margin
‪36.49%‬
Return on Assets
‪9.17%‬
Return on Equity
‪63.01%‬
Ownership
Shares Outstanding
1.76B
Float
1.76B
Held by Insiders
‪0.13%‬
Held by Institutions
‪71.41%‬
Price stats
Beta
‪0.46‬
50-Day Avg
‪247.69‬
200-Day Avg
‪226.65‬
Dividends
Payout Ratio
‪118.93%‬
Frequency
Quarterly
Market Cap - 0QCV - AbbVie Inc.
Peers - 0QCV - AbbVie Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on LSE.
- 0QCVLSEAbbVie Inc.478.52BMarket Cap+21.83%52-week change54.73P/E (Trailing)‪15.50%‬Profit Margin
- AZNLSEAstraZeneca PLC22.41TMarket Cap+29.32%52-week change28.74P/E (Trailing)‪17.18%‬Profit Margin
- GSKLSEGSK plc7.68TMarket Cap+23.40%52-week change16.26P/E (Trailing)‪14.52%‬Profit Margin
- 0QIULSENovo Nordisk A/S1.24TMarket Cap-23.24%52-week change20.09P/E (Trailing)‪33.39%‬Profit Margin
- 0QAHLSEMerck & Co., Inc.383.85BMarket Cap+44.02%52-week change63.23P/E (Trailing)‪5.33%‬Profit Margin
- 0K9ELSENovartis AG Sponsored ADR367.33BMarket Cap+20.90%52-week change0.15P/E (Trailing)‪22.50%‬Profit Margin
- ZEGLSEZegona Communications Plc358.10BMarket Cap+25.06%52-week change167.00P/E (Trailing)‪-5.22%‬Profit Margin
Profile Summary - 0QCV - AbbVie Inc.
About
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
